A000250 Stock Overview
Engages in the manufacturing and sale of pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sam Chun Dang Pharm. Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩118,100.00 |
| 52 Week High | ₩230,000.00 |
| 52 Week Low | ₩61,900.00 |
| Beta | 1.44 |
| 1 Month Change | 2.07% |
| 3 Month Change | -15.10% |
| 1 Year Change | 66.81% |
| 3 Year Change | 177.23% |
| 5 Year Change | 241.82% |
| Change since IPO | 7,014.46% |
Recent News & Updates
Risks Still Elevated At These Prices As Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Shares Dive 26%
Nov 30
Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Investors Are Less Pessimistic Than Expected
Oct 05Sam Chun Dang Pharm (KOSDAQ:000250) Takes On Some Risk With Its Use Of Debt
Sep 08Subdued Growth No Barrier To Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) With Shares Advancing 44%
Jun 19Is Sam Chun Dang Pharm (KOSDAQ:000250) A Risky Investment?
Jun 09Recent updates
Risks Still Elevated At These Prices As Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Shares Dive 26%
Nov 30Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Investors Are Less Pessimistic Than Expected
Oct 05Sam Chun Dang Pharm (KOSDAQ:000250) Takes On Some Risk With Its Use Of Debt
Sep 08Subdued Growth No Barrier To Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) With Shares Advancing 44%
Jun 19Is Sam Chun Dang Pharm (KOSDAQ:000250) A Risky Investment?
Jun 09Optimistic Investors Push Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Shares Up 28% But Growth Is Lacking
Mar 21Sam Chun Dang Pharm (KOSDAQ:000250) Seems To Use Debt Quite Sensibly
Feb 26Investors Who Bought Sam Chun Dang Pharm (KOSDAQ:000250) Shares Five Years Ago Are Now Up 644%
Feb 09Could The Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Ownership Structure Tell Us Something Useful?
Jan 05
Here's Why Sam Chun Dang Pharm (KOSDAQ:000250) Can Manage Its Debt Responsibly
Dec 01Shareholder Returns
| A000250 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 15.8% | 1.5% | -1.6% |
| 1Y | 66.8% | 3.2% | -9.1% |
Return vs Industry: A000250 exceeded the KR Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: A000250 exceeded the KR Market which returned -9.1% over the past year.
Price Volatility
| A000250 volatility | |
|---|---|
| A000250 Average Weekly Movement | 9.6% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A000250's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A000250's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1943 | 409 | Dae-In Yoon | www.scd.co.kr |
Sam Chun Dang Pharm. Co., Ltd engages in the manufacturing and sale of pharmaceutical products in South Korea. It provides ethical and over the counter products in various therapeutic areas comprising ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company is also involved in exporting activities.
Sam Chun Dang Pharm. Co., Ltd Fundamentals Summary
| A000250 fundamental statistics | |
|---|---|
| Market cap | ₩2.75t |
| Earnings (TTM) | ₩5.11b |
| Revenue (TTM) | ₩208.22b |
537.5x
P/E Ratio13.2x
P/S RatioIs A000250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A000250 income statement (TTM) | |
|---|---|
| Revenue | ₩208.22b |
| Cost of Revenue | ₩109.93b |
| Gross Profit | ₩98.29b |
| Other Expenses | ₩93.18b |
| Earnings | ₩5.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 219.72 |
| Gross Margin | 47.20% |
| Net Profit Margin | 2.45% |
| Debt/Equity Ratio | 15.6% |
How did A000250 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 21:20 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sam Chun Dang Pharm. Co., Ltd is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Al Eum Lee | iM Securities |
| Hong-Sik Jeong | LS Securities Co., Ltd. |